Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FNR3Q
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $43,955
Award facts
- Contract value 100% obligated
- $43,954.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $43,954.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on January 9, 2026, with an ultimate completion date of January 12, 2026. The contract is non-set-aside and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor supporting federal military and veteran healthcare systems. The company performs under its parent organization, Cencora, Inc. (doing business as AmerisourceBergen), which holds the primary Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026.
This delivery order represents a task order under the larger pharmaceutical supply framework, which enables AmerisourceBergen to deliver a comprehensive range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs globally. The contract structure and competitive award demonstrate the contractor's capability to efficiently fulfill federal procurement requirements for essential pharmaceutical products needed by military treatment facilities and veteran healthcare programs. Dupixent is a specialty biologic medication primarily used in the treatment of moderate-to-severe atopic dermatitis, eosinophilic asthma, and other allergic and inflammatory conditions commonly managed within military health systems.
Quick answers
Who was awarded contract SPE2DR26FNR3Q?
SPE2DR26FNR3Q was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FNR3Q worth?
The government has obligated $43,955 on SPE2DR26FNR3Q.
Is contract SPE2DR26FNR3Q an order under another contract?
Yes. SPE2DR26FNR3Q is a delivery order under SPE2DR25D1021, an indefinite delivery contract.
Was contract SPE2DR26FNR3Q competed?
The extent of competition for SPE2DR26FNR3Q was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award